Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
LA JOLLA, Calif. (December 6, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…
Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
LA JOLLA, CALIF (November 7, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…
Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting
LA JOLLA, CALIF (October 12, 2022)– Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that…
Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development
LA JOLLA, CALIF (September 27, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…
Calidi Biotherapeutics to Present at Two Upcoming Conferences
LA JOLLA, CALIF (September 8, 2022)– Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that…
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma
LA JOLLA, CALIF–August 2, 2022–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is…